The main focus of synthetic chemistry is to develop safe and therapeutically active compounds by employing green synthetic reaction conditions. The azole nuclei have been the center of attention for decades owing to their diverse pharmacological activities. Various synthetic routes have been identified for the synthesis of pharmacologically active derivatives of azoles. Coupling reactions have gained much importance in synthetic chemistry the most basic type of joining two chemical species. The coupling reactions of azoles include alkylation and arylation of the nitrogen atom which yields many compounds possessing significant therapeutical potential, only having limitations related to expensive catalyst systems, bulky ligands, time constraints etc. These limitations can be overcome by employing safe and economical catalyst systems involving nanoparticles. These nanosystems are easy to formulate and offer the advantage of catalyzing the reaction more rapidly with significantly improved yield. In this review, two of the most important azole nuclei—triazole and benzimidazole—are discussed on the basis of their diverse pharmacological properties making them effective drug candidates for further development to overcome emerging diseases. In particular, 1,2,4-triazole and 2-methlybenzimidazole have wide range of therapeutic activities such as anti-inflammatory, antioxidant, antimicrobial, antidiabetic, anthelmintic, analgesic, antihypertensive, anticonvulsant, anticancer, antiulcer, antiprotozoal, antimycobacterial, anti-HIV and antipsychotic.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11094-022-02730-y/MediaObjects/11094_2022_2730_Fig1_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11094-022-02730-y/MediaObjects/11094_2022_2730_Fig2_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11094-022-02730-y/MediaObjects/11094_2022_2730_Fig3_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11094-022-02730-y/MediaObjects/11094_2022_2730_Fig4_HTML.png)
Similar content being viewed by others
References
P. Lopez-Alvarado, C. Avendano, and J. C. Menendez, J. Org. Chem., 60(17), 5678 – 5682 (1995).
N. V. Suramwar, S. R. Thakare, and N. T. Khaty, Org. Chem. Int., 2012 (2012).
L. Zhu, P. Guo, G. Li, et al., J. Org. Chem., 72(22), 8535 – 8538 (2007).
J. C. Antilla, J. M. Baskin, T. E. Barder, and S. I. Buchwald, J. Org. Chem., 69(17), 5578 – 5587 (2004).
R. Zhu, L. Xing, X. Wang, et al., Adv. Synth. Catal., 350(9), 1253 – 1257 (2008).
D. Wang, F. Zhang, D. Kuang, et al., Green Chem., 14(5), 1268 – 1271 (2012).
V. Sorokin, Mini-Rev. Org. Chem., 5 (4), 323 – 330 (2008).
H. J. Cristau, P. P. Cellier, J. F. Spindler, et al., Chem. Eur. J., 10(22), 5607 – 5622 (2004).
G. Manolikakes, Transition-Metal Catalyzed Cross-Coupling Reactions of Functionalized Organometallic Reagents, Nickel-Catalyzed Amination of Aryl Chlorides, and Preparation and Reactions of Organozinc Reagents (2009).
F. Monnie and M. Taillefer, Angew. Chem. Int. Ed., 48(38), 6954 – 6971 (2009).
F. Monnier and M. Taillefer, Angew. Chem. Int. Ed., 47(17), 3096 – 3099 (2008).
S. Mondal, ChemTexts, 2(4), 1 – 11 (2016).
A. Correa and C. Bolm, Adv. Synth. Catal., 349(17–18), 2673 – 2676 (2007).
L. Rout, T. K. Sen, and T. Punniyamurthy, Angew. Chem., 119(29), 5679 – 5682 (2007).
D. Astruc, Chem. Rev. (Washington, DC), 120(2), 461 – 463 (2020).
A. Alshammari, V. N. Kalevaru, and A. Martin, Metal Nanoparticles as Emerging Green Catalysts, Intech Open Book Series, Vol. 10 (2016), pp. 1 – 33.
F. Gao, T. Wang, J. Xiao, et al., Eur. J. Med. Chem., 173, 274 – 281 (2019).
R. Singh and A. Chouhan, World J. Pharm. Pharm. Sci., 3(8), 874 – 906 (2014).
H. A. El-Sherief, B. G. Youssif, A. H. Abdelazeem, et al., Anti-Cancer Agents Med. Chem., 19(5), 697 – 706 (2019).
V. J. Ram, A. Sethi, M. Nath, et al., The Chemistry of Heterocycles: Nomenclature and Chemistry of Three to Five Membered Heterocycles, Elsevier (2019).
R. A. Altman, E. D. Koval, and S. L. Buchwald, J. Org. Chem., 72(16), 6190 – 6199 (2007).
P. Shojaei, B. Mokhtari, and M. Ghorbanpoor, Med. Chem. Res., 28(9), 1359 – 1367 (2019).
M. Gaba, D. Singh, S. Singh, et al., Eur. J. Med. Chem., 45(6), 2245 – 2249 (2010).
C. Nguyen Tien, D. Tran Thi Cam, H. Bui Manh, et al., J. Chem., 2016 (2016).
C. Beaulieu, Z. Wang, D. Denis, et al., Bioorg. Med. Chem. Lett., 14(12), 3195 – 3199 (2004).
A. Tanitame, Y. Oyamada, K. Ofuji, et al., Bioorg. Med. Chem., 12(21), 5515 – 5524 (2004).
S. Khabnadideh, Z. Rezaei, Y. Ghasemi, et al., Anti-Infect. Agents, 10(1), 26 – 33 (2012).
M. Suresh, S. B. Jonnalagadda, and C. V. Rao, Orient. J. Chem., 27(1), 127 (2011).
K. Kamanna, Synthesis and Pharmacological Profile of Benzimidazoles, in: Chemistry and Applications of Benzimidazole and Its Derivatives, IntechOpen Books (2019).
D. Prasad, N. Aggarwal, R. Kumar, et al., Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem. (2012).
A. Mobinikhaledi, N. Foroughifar, M. Khanpour, et al., Eur. J. Chem., 1(1), 33 – 36 (2010).
M. S. Al-Said, M. M. Ghorab, M. S. Al-Dosari, et al., Eur. J. Med. Chem., 46(1), 201 – 207 (2011).
A. Spasov, I. Yozhitsa, L. Bugaeva, et al., Pharm. Chem. J., 33(5), 232 – 243 (1999).
Y. Bansal and O. Silakari, Bioorg. Med. Chem., 20(21), 6208 – 6236 (2012).
A. P. Thomas, C. P. Allott, K. H. Gibson, et al., J. Med. Chem., 35(5), 877 – 885 (1992).
J. Subbarao, S. Vidhyadhara, and N. Srinivasulu, Int. J. Pharm., 4, 304 – 308 (2014).
B. Jiang, X. Huang, H. Yao, et al., Org. Biomol. Chem., 12(13), 2114 – 2127 (2014).
R. C. Corrales, N. B. De Souza, L. S. Pinheiro, et al., Biomed. Pharmacother., 65(3), 198 – 203 (2011).
J. K. Shneine and Y. H. Alaraji, Int. J. Sci. Res., 9(9b), 9c (2016).
B. K. Prajapati and D. J. Sen, Am. J. Adv. Drug Delivery, 1(1), 151 – 159 (2013).
A. Husain, M. Varshney, M. Rashid, et al., J. Pharm. Res, 4(2), 413 – 419 (2011).
Acknowledgments
The authors would like to acknowledge continuous support by Pharmacy Departments of the Quaid-i-Azam University and the Shifa Tameer-e-Millat University, Islamabad.
CONFLICT OF INTEREST
The authors declare that they have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Waseem, T., Ullah, N. & Rajput, T.A. Review of Synthetic Accessibility And Pharmacological Activity of 1,2,4-Triazole and 2-Methylbenzimidazole Derivatives. Pharm Chem J 56, 943–947 (2022). https://doi.org/10.1007/s11094-022-02730-y
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-022-02730-y